Ionis Pharma – AstraZeneca Antisense Medicine Met Its Primary, Secondary Goals To Lower Cholesterol
Ionis Pharmaceuticals Inc (NASDAQ: IONS) and its partner, AstraZeneca Plc (NASDAQ: AZN), have
Mitt Romney Says Senators Reached Tentative $10B Deal In Additional COVID-19 Relief Funding: CNBC
Senate Republicans and Democrats have reportedly reached a tentative deal on $10 billion in additional COVID-19 funding to shore up…
AstraZeneca Announced Evusheld Approved in the EU for Pre-exposure Prophylaxis of COVID-19 in People 12 and Older
vusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months.
Evusheld retains neutralising activity against the Omicron BA.2 subvariant, now the dominant strain in Europe.
AstraZeneca Says Evusheld Long-Acting Antibody Combination Recommended For Approval In The EU For The Pre-Exposure Prophylaxis
https://news.cision.com/se/astrazeneca/r/evusheld-long-acting-antibody-combination-recommended-for-approval-in-the-eu-for-the-pre-exposure-pr%2Cc3532176
EMA Recommends Approval Of AstraZeneca’s COVID-19 Therapy, Evusheld
EMA's human medicines committee (CHMP) has